Laurus Labs has informed that development is underway based on an agreement launched in June 2021 between the Company, Unitaid and the Clinton Health Access Initiative (CHAI), to accelerate the development, commercialization, and registration of the best-in-class second- and third-line HIV treatment darunavir boosted with ritonavir (DRV/r) for children. Despite being available in high-income countries for over a 15-year period, a generic, fixed-dose combination pediatric version of DRV/r is still not available. Through this agreement, Unitaid and CHAI are working with the Company to finally address this critical need and ensure CLHIV (Children Living with HIV/AIDS) have access to high-quality second- and third-line HIV treatment. A press release to this extent is also enclosed for information and records.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1884.50 |
Dr. Reddys Lab | 1388.25 |
Cipla | 1529.50 |
Lupin | 2350.95 |
Zydus Lifesciences | 971.45 |
View more.. |